KR101894702B1 - 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 - Google Patents

함질소 지환식 골격을 갖는 일본쇄 핵산 분자 Download PDF

Info

Publication number
KR101894702B1
KR101894702B1 KR1020187010011A KR20187010011A KR101894702B1 KR 101894702 B1 KR101894702 B1 KR 101894702B1 KR 1020187010011 A KR1020187010011 A KR 1020187010011A KR 20187010011 A KR20187010011 A KR 20187010011A KR 101894702 B1 KR101894702 B1 KR 101894702B1
Authority
KR
South Korea
Prior art keywords
region
nucleic acid
acid molecule
expression
bases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187010011A
Other languages
English (en)
Korean (ko)
Other versions
KR20180040728A (ko
Inventor
다다아키 오기
히로타케 하야시
히사오 시로즈
도모히로 하마사키
아키히로 이토
히로시 스즈키
Original Assignee
가부시키가이샤 보낙
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 보낙 filed Critical 가부시키가이샤 보낙
Publication of KR20180040728A publication Critical patent/KR20180040728A/ko
Application granted granted Critical
Publication of KR101894702B1 publication Critical patent/KR101894702B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187010011A 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 Expired - Fee Related KR101894702B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JPJP-P-2010-174915 2010-08-03
JP2010174915 2010-08-03
JP2010230806 2010-10-13
JPJP-P-2010-230806 2010-10-13
JP2010269823 2010-12-02
JPJP-P-2010-269823 2010-12-02
JPJP-P-2011-152381 2011-07-08
JP2011152381 2011-07-08
PCT/JP2011/067292 WO2012017919A1 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137004646A Division KR101849801B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Publications (2)

Publication Number Publication Date
KR20180040728A KR20180040728A (ko) 2018-04-20
KR101894702B1 true KR101894702B1 (ko) 2018-09-04

Family

ID=45559420

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187010011A Expired - Fee Related KR101894702B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020187010010A Active KR101894701B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020137004646A Expired - Fee Related KR101849801B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187010010A Active KR101894701B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
KR1020137004646A Expired - Fee Related KR101849801B1 (ko) 2010-08-03 2011-07-28 함질소 지환식 골격을 갖는 일본쇄 핵산 분자

Country Status (10)

Country Link
US (3) US8691782B2 (https=)
EP (4) EP2639307B1 (https=)
JP (3) JP4965745B2 (https=)
KR (3) KR101894702B1 (https=)
CN (3) CN104004018B (https=)
DK (1) DK2674494T3 (https=)
ES (4) ES2527660T3 (https=)
PT (1) PT2674494E (https=)
TW (2) TWI515294B (https=)
WO (1) WO2012017919A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2639307B1 (en) 2010-08-03 2015-03-04 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
EP2824184B1 (en) * 2012-03-04 2017-09-27 Bonac Corporation micro-RNA INHIBITOR
WO2013133393A1 (ja) * 2012-03-07 2013-09-12 学校法人東京医科大学 Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子
CA2868716A1 (en) * 2012-03-29 2013-10-03 Kyushu University National University Corporation Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US20160304866A1 (en) * 2013-09-27 2016-10-20 Aqua Therapeutics Co., Ltd. Drug for Disease Caused by Expression of Periostin Except Eye Disease, and Use Thereof
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
JP6492014B2 (ja) * 2013-12-27 2019-03-27 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
CN106068324B (zh) * 2013-12-27 2020-12-29 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
EP3235906B1 (en) * 2014-12-15 2021-06-23 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
KR20170098914A (ko) * 2014-12-27 2017-08-30 가부시키가이샤 보낙 유전자 발현 제어를 위한 천연형 miRNA 및 그의 용도
BR112017014090A2 (pt) * 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
US20180099004A1 (en) * 2015-04-17 2018-04-12 The University Of Tokyo Therapeutic agent for eye disease
SG11201803410RA (en) 2015-10-30 2018-05-30 Bonac Corp COMPOSITION STABLY CONTAINING SINGLE-STRANDED NUCLEIC ACID MOLECULE THAT SUPPRESSES EXPRESSION OF TGF-ß1 GENE
MX2018008086A (es) * 2015-12-29 2018-11-12 Univ Hokkaido Nat Univ Corp Molecula de acido nucleico monocatenario que inhibe la expresion del gen de prorrenina o el gen del receptor de prorrenina y uso de la misma.
WO2017131124A1 (ja) 2016-01-26 2017-08-03 日産化学工業株式会社 一本鎖オリゴヌクレオチド
CN109072224B (zh) * 2016-01-30 2022-07-15 株式会社博纳克 人工单导rna及其用途
EP3450439B8 (en) * 2016-04-26 2021-06-30 Sumitomo Chemical Company, Limited Method for producing monomer for single-stranded nucleic acid molecule
AU2018215440B2 (en) 2017-02-06 2024-10-24 Nissan Chemical Corporation Single-stranded oligonucleotide
JPWO2018182008A1 (ja) 2017-03-31 2020-02-06 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
JPWO2018199338A1 (ja) * 2017-04-27 2020-03-12 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
EP3659609B1 (en) * 2017-07-28 2024-05-08 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
US20210188895A1 (en) 2017-10-13 2021-06-24 Bonac Corporation Single-stranded nucleic acid molecule, and production method therefor
TWI830718B (zh) 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
BR112020018902A2 (pt) 2018-03-20 2021-01-26 Tokyo Institute Of Technology oligonucleotídeo antissenso com toxicidade reduzida
JP6817493B2 (ja) * 2018-03-30 2021-01-20 住友化学株式会社 一本鎖ｒｎａの製造方法
US11920131B2 (en) 2018-03-30 2024-03-05 Toray Industries, Inc. Method of producing hairpin single-stranded RNA molecule
KR102670605B1 (ko) * 2018-04-24 2024-05-29 스미또모 가가꾸 가부시끼가이샤 아미다이트 화합물 및 그 화합물을 사용한 폴리뉴클레오티드의 제조 방법
KR20210069628A (ko) 2018-10-02 2021-06-11 도레이 카부시키가이샤 헤어핀형 단일쇄 rna 분자의 제조 방법
WO2020152869A1 (ja) 2019-01-25 2020-07-30 杏林製薬株式会社 線維症治療剤
JP7510919B2 (ja) 2019-03-29 2024-07-04 住友化学株式会社 無機多孔質担体及びこれを用いた核酸の製造方法
WO2020202951A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
WO2020202953A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
WO2020202949A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 Ｒｎａの製造方法
JP7368455B2 (ja) 2019-03-29 2023-10-24 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
JP7640461B2 (ja) 2019-10-11 2025-03-05 住友化学株式会社 核酸オリゴマーの製造方法
EP4098655A4 (en) 2020-01-29 2024-02-28 Sumitomo Chemical Company, Limited METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS
JP7667788B2 (ja) 2020-01-29 2025-04-23 住友化学株式会社 核酸オリゴマーの製造方法
EP4130018A4 (en) * 2020-03-27 2024-04-17 Sumitomo Chemical Company, Limited METHOD FOR PRODUCING A NUCLEIC ACID OLIGOMER
WO2021230293A1 (ja) 2020-05-13 2021-11-18 住友化学株式会社 無機多孔質基材、無機多孔質担体、および核酸の製造方法
CN115867559A (zh) 2020-07-09 2023-03-28 住友化学株式会社 核酸寡聚物的制造方法
KR20230074205A (ko) * 2020-09-24 2023-05-26 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
CN117980285A (zh) 2021-09-28 2024-05-03 住友化学株式会社 纯化二氯乙酸的制造方法
US12509485B2 (en) 2022-03-23 2025-12-30 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076321A1 (en) 2003-02-28 2004-09-10 Fountain Patents B.V. System and method for storage and transport of sea containers

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) * 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
AU2004266311B2 (en) * 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003219900A1 (en) * 2002-02-22 2003-09-09 James R. Eshleman Antigene locks and therapeutic uses thereof
AU2003224725A1 (en) 2002-03-20 2003-10-08 Brigham And Women's Hospital, Inc. Hiv therapeutic
DE60310944T3 (de) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Weitere neue formen von interferierende rns moleküle
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
WO2004090108A2 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
CN1860228B (zh) * 2003-09-30 2010-04-28 安琪士摩奇株式会社 订书钉型寡核苷酸及包含该订书钉型寡核苷酸的药物
EP1789553B1 (en) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
US20090005332A1 (en) * 2004-12-30 2009-01-01 Hauser Todd M Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
EP2129680B1 (en) * 2007-03-21 2015-05-06 Brookhaven Science Associates, LLC Combined hairpin-antisense compositions and methods for modulating expression
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US20110212075A1 (en) * 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
US20100317714A1 (en) 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
WO2009073809A2 (en) * 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110159586A1 (en) * 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
US20110055965A1 (en) 2008-02-15 2011-03-03 Hiroshi Abe Cycle single-stranded nucleic acid complex and method for producing the same
JP2010174915A (ja) 2009-01-27 2010-08-12 Toyota Motor Corp 高圧ガスタンク
JP5449815B2 (ja) 2009-03-26 2014-03-19 住友化学株式会社 偏光板の製造方法
JP2010269823A (ja) 2009-05-21 2010-12-02 British American Tobacco Japan Kk 喫煙品用容器
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
JP2011152381A (ja) 2010-01-25 2011-08-11 Ucom:Kk 箸置き
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
EP2562257A4 (en) 2010-04-19 2014-10-01 Riken PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS
EP2933333B1 (en) 2010-07-08 2018-02-21 Bonac Corporation Single-strand nucleic acid molecule for controlling gene expression
EP2639307B1 (en) 2010-08-03 2015-03-04 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076321A1 (en) 2003-02-28 2004-09-10 Fountain Patents B.V. System and method for storage and transport of sea containers

Also Published As

Publication number Publication date
TWI572716B (zh) 2017-03-01
KR101894701B1 (ko) 2018-09-04
EP2436767B1 (en) 2013-11-20
CN103052711A (zh) 2013-04-17
ES2443346T3 (es) 2014-02-19
KR101849801B1 (ko) 2018-04-17
US9200278B2 (en) 2015-12-01
CN104059911A (zh) 2014-09-24
US8691782B2 (en) 2014-04-08
DK2674494T3 (en) 2015-02-23
JP2013138681A (ja) 2013-07-18
ES2533129T3 (es) 2015-04-07
HK1200460A1 (zh) 2015-08-07
KR20180040728A (ko) 2018-04-20
TWI515294B (zh) 2016-01-01
US20140171486A1 (en) 2014-06-19
US9206422B2 (en) 2015-12-08
CN104004018A (zh) 2014-08-27
EP2639307B1 (en) 2015-03-04
CN104004018B (zh) 2017-01-04
ES2527660T3 (es) 2015-01-28
EP2628801B1 (en) 2015-01-07
US20120035246A1 (en) 2012-02-09
EP2674494B1 (en) 2014-12-17
EP2628801A1 (en) 2013-08-21
ES2528285T3 (es) 2015-02-06
TW201219570A (en) 2012-05-16
TW201615835A (zh) 2016-05-01
JP5261677B2 (ja) 2013-08-14
JP2013034470A (ja) 2013-02-21
CN104059911B (zh) 2017-01-04
JPWO2012017919A1 (ja) 2013-10-03
EP2674494A1 (en) 2013-12-18
HK1189910A1 (en) 2014-06-20
CN103052711B (zh) 2016-08-03
JP4965745B2 (ja) 2012-07-04
EP2639307A3 (en) 2014-02-05
EP2639307A2 (en) 2013-09-18
EP2436767A4 (en) 2012-05-09
KR20180040727A (ko) 2018-04-20
EP2436767A1 (en) 2012-04-04
WO2012017919A1 (ja) 2012-02-09
KR20130095738A (ko) 2013-08-28
EP2639307A8 (en) 2014-04-30
PT2674494E (pt) 2015-02-27
US20140171633A1 (en) 2014-06-19
JP5555346B2 (ja) 2014-07-23

Similar Documents

Publication Publication Date Title
KR101894702B1 (ko) 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
JP6162182B2 (ja) 遺伝子発現制御のための一本鎖核酸分子
KR101674778B1 (ko) 아미노산 골격을 갖는 단일-가닥 핵산 분자
WO2013077446A1 (ja) 遺伝子発現制御のための一本鎖核酸分子
JP2013055913A (ja) 遺伝子発現制御のための一本鎖ｒｎａ分子
HK1200460B (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
HK1181423B (en) Single-strand nucleic acid molecule for controlling gene expression

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240829

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240829